SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-034510
Filing Date
2023-10-17
Accepted
2023-10-17 16:02:27
Documents
13
Period of Report
2023-10-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20231016.htm   iXBRL 8-K 27189
2 EX-3.1 ex31_fourtharbylaws.htm EX-3.1 148005
  Complete submission text file 0001628280-23-034510.txt   330959

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20231016.xsd EX-101.SCH 1969
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20231016_lab.xml EX-101.LAB 24183
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20231016_pre.xml EX-101.PRE 12576
7 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20231016_htm.xml XML 2725
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 231329628
SIC: 2834 Pharmaceutical Preparations